Literature DB >> 30320666

Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease.

Stanley Cho1, Elizabeth Spencer1, Robert Hirten2, Ari Grinspan2, Marla C Dubinsky1.   

Abstract

OBJECTIVES: Recurrent Clostridium difficile infection (RCDI) increases morbidity and mortality in patients with inflammatory bowel disease (IBD). Fecal microbiota transplant (FMT) is known to be very effective for RCDI in non-IBD patients with cure rates up to 91%. The same success rates of FMT have not been reported in patients with IBD with RCDI, and the data in pediatrics are limited. We aimed to determine the effectiveness of FMT for RCDI in established pediatric patients with IBD.
METHODS: We performed a retrospective chart review of pediatric patients with IBD and RCDI (≥3 episodes) who underwent FMT via colonoscopy at a tertiary care IBD center. The primary outcome was the rate of RCDI within 60 days post-FMT. The secondary outcomes were recurrence rate by 6 months, rate of colectomy, and time to recurrence.
RESULTS: Of the 8 eligible patients, 6 had ulcerative colitis, 1 had IBD-unspecified, and 1 had Crohn disease. Median (interquartile range) age was 13 (11-14) years. All patients were on vancomycin at FMT. Two patients (25%) had RCDI by 60 days post-FMT and another 3 patients had RCDI between 60 days and 6 months. The median time to recurrence was 101 (40-139) days. Two patients (25%) who developed recurrence went to colectomy after FMT.
CONCLUSIONS: With a cure rate of 75% at 60 days, FMT administered for the treatment of RCDI may be an effective treatment option in pediatric IBD. However, there appears to be a significant rate of late recurrence of C difficile infection after 60 days in these patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30320666     DOI: 10.1097/MPG.0000000000002172

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.

Authors:  Shane J Cross; Theodore H Morton; Joshua Wolf
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 3.164

Review 2.  Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Authors:  Rachel Bernard; Suchitra K Hourigan; Maribeth R Nicholson
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

Review 3.  Circulating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function.

Authors:  Amedeo Amedei; Lucia Morbidelli
Journal:  Molecules       Date:  2019-11-05       Impact factor: 4.411

Review 4.  The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease.

Authors:  Craig Haifer; Rupert W Leong; Sudarshan Paramsothy
Journal:  Curr Opin Pharmacol       Date:  2020-10-07       Impact factor: 5.547

Review 5.  Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation.

Authors:  Paulina Żebrowska; Izabela Łaczmańska; Łukasz Łaczmański
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

6.  Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma.

Authors:  Máire A Conrad; Judith R Kelsen
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

7.  Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.

Authors:  M Olmedo; M Kestler; M Valerio; B Padilla; C Rodríguez González; E Chamarro; M Machado; A Álvarez-Uría; L Alcalá; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2022-03-14       Impact factor: 2.515

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.